anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to hydrous liquid paste or cream-like hand cleansing agents without organic solvents, especially a course hand cleanser with a rubbing agent. Said cleansing agents are characterized by a content of 10 to 30 wt. % of at least one vegetable oil from the group of triglycerides, saturated and/or unsaturated fatty acids, of 10 to 30 wt % of a tenside composition comprised of a fatty alcohol ethoxylate, at least one fatty alcohol ether sulfate and/or a salt of a sulfonated fatty acid, 10 to 65 wt. % water, each referring to the composition of the cleansing agent, and optionally 1 to 30 wt. % of at least one abrasive. In addition, the hand cleanser optionally contains at least one viscosity building agent and optional additional cosmetic auxiliary, accessory and/or active agents.
PURPOSE: A pharmaceutical composition containing Iris nertschinskia extract for preventing and treating cancer is provided to induce cancer cell apoptosis by caspase activation. CONSTITUTION: A pharmaceutical composition for preventing and treating cancer contains 0.1-50 weight% of Iris nertschinskia extract as an active ingredient. The Iris nertschinskia extract is isolated from seed of Iris nertschinskia. The cancer is breast cancer. A method for preparing the Iris nertschinskia extract comprises: a step of pulverizing Iris nertschinskia seeds and extracting with a solvent to obtain crude extract; a step of decompressing the crude extract to obtain original extract; and a step of freeze-drying the original extract and dissolving in DMSO. A food composition for preventing and suppressing cancer contains the Iris nertschinskia extract as an active ingredient.
Advances in immunosuppressive therapies in pediatrics have been associated with rapidly falling incidence of acute rejection and improving allograft survival. In recent analyses of the NAPRTCS database, acute rejection is no longer the most common cause of hospitalization or allograft failure. Chronic rejection has now become the most common cause of allograft failure and accounts for over 35% of allograft loss. Chronic rejection is a complex clinical condition that includes both immunologic and non-immunologic causes and is more accurately referred to as Chronic Allograft Nephropathy (CAN). Although Calcineurin inhibitors (CNI) have played a central role in reducing acute rejection and improving allograft survival, it has long been shown that they contribute to interstitial fibrosis and chronic allograft nephropathy. Recent trials in adult transplantation have demonstrated that with the use of the TOR-inhibitor, Sirolimus, it is possible to withdraw Calcineurin inhibitors with no increase in rejection and with improvements in allograft function, interstitial fibrosis and long term survival (1). We hypothesize that the use of Sirolimus (SRL) in pediatric kidney transplantation will allow the withdrawal of Calcineurin inhibitor and improved kidney function and long term survival. We plan to enroll 50 patients at the time of transplantation. Patients will receive routine immunosuppression of CNI (Prograf), Mycophenolate mofetil (Cellcept) and prednisone. Those patients with normal function and no rejection episodes after 6 months of transplantation will undergo a slow conversion from Prograf to Sirolimus (Rapamune). We will then assess the rate of rejection, allograft function, fibrosis on biopsy, and allograft survival over the following 18 months.
OBJECTIVES: I. Evaluate the efficacy of weekly docetaxel as measured by disease response, strength and duration of pain reduction, and either a decrease in analgesic use without an increase in pain, or a decrease in PSA, in patients with hormone refractory metastatic prostate cancer. II. Assess the efficacy of this regimen in terms of survival in this patient population. III. Evaluate the effect of this regimen on quality of life in these patients. IV. Determine qualitative and quantitative toxicities of this regimen in these patients.

OUTLINE: Patients receive docetaxel IV over 15-30 minutes weekly for 6 weeks. Courses repeat every 8 weeks. Therapy continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at weeks 1, 3, 5, and 7 of each course, and a daily pain medication diary is maintained during treatment. Patients are followed for 1 month or until resolution of toxicity, then every 3 months until death.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Cancer risks attributable to low-dose and low-dose-rate radiation are a serious concern for public health. Radiation risk assessment is based on lifespan studies among Hiroshima-Nagasaki A-bomb survivors; however, there are statistical limitations due to a small sample size for low-dose radiation. Therefore, basic biological studies are helpful in understanding the mechanism of radiation carcinogenesis. The detrimental effects of ionising radiation (IR) are caused by reactive oxygen species (ROS)-mediated oxidative DNA damage. IR-induced delayed ROS are produced in the electron transport chain reaction of the mitochondrial complex. Thus, mitochondria are a source of ROS and a primary target for ROS attacks. Consequently, mitochondrial dysfunction is thought to be a key event in the metabolic changes of cancer cells and is important in radiation-induced carcinogenesis. In this paper, we present recent findings on radiation carcinogenesis effect assessment, focusing on mitochondrial function as stress sensors.
<P>PROBLEM TO BE SOLVED: To provide two kinds of new proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2.  <P>SOLUTION: Each of the new proteins encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by MAb 17C7. One or more of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Synthesized products and both diagnostic and curative methods for the treatment and study of M. catarrhalis are also provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
ETHNOPHARMACOLOGICAL RELEVANCE: The prevalence of colitis is on the rise, and effective treatment options are currently lacking. Xihuang pill (XHP) is a traditional Chinese medicine formula mentioned in the "Volume 4 of Surgical Evidence and Treatment of the Whole Life" authored by the renowned doctor Hong-Xu Wang during the Qing Dynasty. It is now part of the "Volume 9 of Chinese medicine formula preparation in Drug Standard." XHP and its primary ingredients have been demonstrated anti-inflammatory properties against colitis. However, the specific effects and underlying mechanisms of XHP in treating colitis remain unknown.
AIM OF THE STUDY: This study aimed to investigate the potential impact of XHP on colitis and uncover the underlying mechanisms involved.
MATERIALS AND METHODS: An acute colitis model was developed in C57BL/6N mice, and the effects on weight loss, colon length, the permeability of the colonic mucosa barrier, Claudin-5 and Occludin expression, number of both infiltrating MPO-positive cells and CD68-positive cells, and the content of pro-inflammatory cytokines (IL-6, IL-22, IL-1β, and TNF-α) in the colon tissue were investigated. Low-, medium-, and high-dose XHP (0.45, 0.9, and 1.8 g/kg/day) (batch number: z21021222) were administered to the mice by gavage over the course of two weeks. Additionally, the protein expression levels in colon tissue from the control group, colitis group, and XHP low-dose administration group mice were analyzed by quantitative proteomics techniques. The comprehensive profiling and characterization of absorbed components in mice blood following oral administration of XHP were identified by HPLC/Q-TOF-MS techniques, and the absorbed components in blood were combined with proteomics to reveal the mechanism of enteritis inhibition by XHP.
RESULTS: Our findings indicated that XHP enhanced weight loss and colonic shortening of colitis mice. Additionally, XHP reduced the increase in permeability of the colonic mucosa barrier and decreased expression of Claudin-5 and Occludin, while significantly reducing the number of infiltrating MPO-positive cells and CD68-positive cells in the colon tissue. We found that XHP reduced the production of pro-inflammatory cytokines, including IL-6, IL-22, IL-1β, and TNF-α in colon tissue. Pharmacokinetic analysis suggested that XHP contained 24 blood-entering prototype ingredients, which improved colitis through the regulation of various proteins (e.g., Ctsb, Sting1, and Abat) linked to mucosal barrier injury and inflammation.
CONCLUSION: XHP improved intestinal mucosal barrier injury and reduced MPO-positive cells and CD68-positive cell infiltration through multiple targets and pathways, providing support for XHP as a promising therapy for colitis.
The present invention relates in a first aspect to a method for the prediction of a survival rate of an individual within a predetermined time period or at a predetermined time end point, whereby a body fluid sample from the individual is analysed and based on the information of peptidome/proteome present in said body fluid, the survival rate of said individual within the predetermined time period or at a predetermined time end point is calculated. Further, the present invention applies a specific predetermined multidimensional classifier for calculating the survival rate. That is, the survival rate reflects the probability of future death within the predetermined time period or the predetermined time end point. The method includes in an embodiment artificial intelligence routine. The individuals analysed include individuals with pre-existing conditions as well as healthy individuals. Moreover, a computer implemented method for the prediction of the survival rate of an individual is provided as well as a computer readable medium or computer program product having computer executable instructions for performing the method according to the present invention.
The present invention is generally directed to potassium adenosine triphosphate ('KATP') channel opening compositions. The present invention also relates to the use of KATP channel openers in therapeutic applications. The KATP channel opening compositions of the present invention include diazoxide (7-chloro-3-methyl-2H-1,2,4-benzo-thiadiazine 1,1-dioxide) and aprikalim. According to the present invention, diazoxide and aprikalim can be used independently, or in combination. The present also relates to therapeutic methods for protecting neuronal function utilizing KATP channel openers. Methods of the present invention may be advantageous for protecting neuronal function, prior to medical procedures, after stroke-like events or other events associated with reductions in blood flow, and/or for preserving tissues or organs against cellular injury and death during removal, storage, transplantation or reattachment.
The invention comprises a water-soluble, substantially non-ionic complex of ferric hydroxide with a degraded pectin, said pectin having an average intrinsic viscosity at 25 DEG  C. in the range of 0.04 to 0.25.  The complex may contain 13.1 to 14.9% by weight of elemental iron, and may be made by mixing an aqueous solution of a degraded pectin having an average intrinsic viscosity at 25 DEG  C. of 0.04 to 0.25, with an aqueous solution of a ferric salt, e.g. ferric chloride, nitrate, sulphate, acetate, or ferric ammonium sulphate, and forming ferric hydroxide in situ by addition of an alkaline material, e.g. sodium hydroxide, to the reaction mixture. After removal of insoluble matter by filtration, or centrifugation, and low-molecular weight material by dialysis, the complex may be precipitated from aqueous solution by an organic solvent, e.g. methanol, washed and dried. The complex forms injectable aqueous solutions of low viscosity containing up to 100 mg. of iron per ml. (Divisions A5-A6). Degraded pectin having the required viscosity may be prepared by adding pectin to water at 60-70 DEG  C. to form a homogeneous solution of pectin containing 10-20% by weight of pectin, adding 3-10% by weight of pectinase, based on the weight of pectin, then adding, preferably after 6-8 hours; and again after about 24 hours, additional amounts of pectinase (approximately 1% based on the weight of pectin), and then, after about 48 hours, removing insoluble material from the pectin solution.  In an example, the degraded pectin has an intrinsic viscosity at 25 DEG  C. of 0.045, corresponding to a molecular weight of 2200.ALSO:An injectable solution containing up to 100 mg of iron per ml comprises an aqueous solution of a substantially non-ionic complex of ferric hydroxide with a degraded pectin, said degraded pectin having an intrinsic viscosity at 25 DEG C. of 0.04 to 0.25.  The solution may be made isotonic by addition of common salt, and a preservative e.g. phenol, may be added.  The solution may be used intramuscularly for the treatment of iron deficiency anaemia.
To provide a data processing method capable of improving work efficiency for processing metadata associated with a still image, a data processing device, and a program.SOLUTION: A data processing method includes an information display step, a position selection step, and a processing step. In the information display step, a display control unit displays position information indicating the positional relationship between two or more positions in a three-dimensional space containing an object on a display. Position data indicates the two or more positions. In the position selection step, a selection unit selects at least one position included in the two or more positions. In the processing step, a data processing unit processes metadata. The metadata is associated with a still image. The still image is associated with the at least one selected position.SELECTED DRAWING: Figure 1
Neutropenic sepsis (NS) is one of the leading causes of death among patients with hematologic malignancies. Identifying its predictive factors is fundamental for early detection. Few studies have evaluated the predictive factors in relation to microbial infection confirmation, which is clinically important for initiating sepsis treatment. This study aimed to determine whether selected biomarkers (i.e., body temperature, C-reactive protein, albumin, procalcitonin), treatment-related characteristics (i.e., diagnosis, duration of neutropenia, treatment modality), and infection-related characteristics (i.e., infection source, causative organisms) can predict NS in patients with hematologic malignancies. We also aimed to identify the optimal predictive cutoff points for these parameters. This retrospective case-control study used the data from a total of 163 patients (58 in the sepsis group and 105 in the non-sepsis group). We collected data with reference to the day of specimen collection, with which microbial infection was confirmed. Multiple logistic regression was used to determine predictive risk factors and the area under the curve (AUC) of the receiver operating characteristic for the optimal predictive cutoff points. The independent predictors of NS were average body temperature during a fever episode and procalcitonin level. The odds for NS rose by 9.97 times with every 1°C rise in average body temperature (95% confidence interval, CI [1.33, 75.05]) and by 2.09 times with every 1 ng/mL rise in the procalcitonin level (95% CI [1.08, 4.04]). Average body temperature (AUC = 0.77, 95% CI [0.68, 0.87]) and procalcitonin levels (AUC = 0.71, 95% CI [0.59, 0.84]) have fair accuracy for predicting NS, with the optimal cutoff points of 37.9°C and 0.55 ng/mL, respectively. This study found that average body temperature during a fever episode and procalcitonin are useful in predicting NS. Thus, nurses should carefully monitor body temperature and procalcitonin levels in patients with hematologic malignancies to detect the onset of NS.
The present invention provides a chemical class of active agents to be used as efficacious drugs in preventing erythrocyte dehydration, thus helping ameliorate the symptoms of certain hemoglobinopathies. The active agents include a class of compounds that can deliver to an erythrocyte in vivo a divalent cation. Increased intracellular concentrations of the divalent cation in the erythrocyte block K—Cl cotransport preventing dehydration of the erythrocyte, thus improving erythrocyte survival. These agents are to be administered by any preferred route of administration including oral, intravenous and parenteral routes. These agents may be co-administered with any other anti-hemoglobinopathic compounds. The methodology is effective for both long term and short term therapy; may be employed prophylactically and/or therapeutically; and may be used in acute crisis clinical situations.
FIELD: medicine. SUBSTANCE: method involves extracting vegetable material like Odontites vulgaris herb with 35-45% ethyl alcohol in 1:(12-14) raw material - extractant proportion taking into account water absorption coefficient. The process takes 60 min at 60-65 C and constant stirring. The process is repeated two times. The third extraction is carried out in the same mode during 30 min. Mixed water-alcohol extraction stuff is filtered, boiled down to 1/3 of the initial volume. The rest in cube is processed with separation. The obtained product is boiled down to 1/3 of the initial volume and dried in vacuum-type drying box. EFFECT: higher cholagogue and anti-inflammation activity. 13 tbl
INVOS : Cerebral oxygenation (rSO2) monitoring with INVOS. If rSO2 decreased for more than 20% from patient's baseline value, simple interventions were performed to prevent brain injury. These interventions included: repositioning of head or perfusion cannulae, increasing arterial carbon dioxide tension, increasing oxygen inspiration concentration, increasing arterial blood pressure, adjusting pump flow rate, temperature decreasing, increasing of anesthetic depth and blood transfusion.
Pelvic organ prolapse (POP) is a significant health concern that has a negative impact on the physical and psychological well-being of women. In fact, the lifetime risk of undergoing POP surgery is 12.6%. The most common form of POP involves defects in the anterior vaginal wall accompanied by apical prolapse. The primary goal of surgical treatment for POP is to alleviate symptoms and restore the anatomy of the pelvic support. The normal position of the vaginal axis is directed posteriorly towards the S3 and S4 vertebrae, lying relatively horizontally to the levator plate, and forming an angle of about 130º between the middle and lower vagina. Sacrocolpopexy (SCP) is considered the gold standard for treating POP, but it alters the normal anatomical position of the vaginal axis towards the sacral promontory, which may increase the abdominal pressure load on the anterior wall and cause urge symptoms or de novo anterior compartment prolapse. Although sacrospinous ligament fixation (SSLF) has promising long-term outcomes for correcting the apical anatomy, it increases the risk of anterior vaginal wall prolapse, like SCP, due to the deviation of the vaginal axis towards the posterior. Recently, laparoscopic lateral mesh suspension, which keeps the vaginal axis close to normal, has become popular. In a previous study, it was found that the pectineal ligament (Cooper's ligament) is composed of stronger and more durable tissue than the sacrospinous ligament and arcus tendineus of the fascia pelvis. This structure is robust and can hold sutures well. Sufficient material for a suture can also be found in the lateral part of the iliopectineal ligament, making pelvic floor reconstruction easier. This segment of the ligament is located at the second sacral vertebra (S2) level, which is the optimal level for the physiological axis of the vagina. S2 level is the anchor point for the physiological axis of the vagina. Further studies have demonstrated comparable outcomes for supporting the apical compartment at intermediate follow-up duration compared to laparoscopic sacrocolpopexy. This study aimed to investigate the level of anatomical correction following Laparoscopic pectopexy and compare the vaginal axis of patients with apical genital prolapse to that of nulliparous women using magnetic resonance imaging (MRI).
BACKGROUND: This parallel, randomized controlled trial examined intrinsic motivation, adherence and motor function improvement demonstrated by two groups of subjects that performed a 12-week, home-based upper extremity rehabilitation program. Seventeen subjects played scaffolded games, presenting eight to twelve discrete levels of increasing difficulty. Sixteen subjects performed the same activities controlled by success algorithms that modify game difficulty incrementally.
METHODS: 33 persons 20-80 years of age, at least 6 months post stroke with moderate to mild hemiparesis were randomized using a random number generator into the two groups. They were tested using the Action Research Arm Test, Upper Extremity Fugl Meyer Assessment, Stroke Impact Scale and Intrinsic Motivation Inventory pre and post training. Adherence was measured using timestamps generated by the gaming system. Subjects had the Home Virtual Rehabilitation System (Qiu in J Neuroeng Rehabil 17: 1-10, 2020) placed in their homes and were taught to perform rehabilitation games using it. Subjects were instructed to train twenty minutes per day but were allowed to train as much as they chose. Subjects trained for 12 weeks without appointments and received intermittent support from study staff. Group outcomes were compared using ANOVA. Correlations between subject demographics and adherence, as well as motor outcome, were evaluated using Pearson Correlation Coefficients.
RESULTS: There were 5 dropouts and no adverse events. The main effect of time was statistically significant for four of the five clinical outcome measures. There were no significant training group by time interactions. Measures of adherence did not differ significantly between groups. The combined groups improved their UEFMA scores on average by 5.85 (95% CI 4.73-6.98). 21 subjects from both groups demonstrating improvements in UEFMA scores of at least 5 points, exceeding the minimal clinically important difference of 4.25. IMI scores were stable pre to post training.
CONCLUSIONS: Scaffolding challenges during game based rehabilitation did not elicit higher levels of adherence when compared to algorithm control of game difficulty. Both sparsely supervised programs of game-based treatment in the home were sufficient to elicit statistically significant, clinically meaningful improvements in motor function and activities of daily living.
TRIAL REGISTRATION: Clinical Trials.gov-NCT03985761, Registered June 14, 2019.
Long‑term studies in animals have not been performed to evaluate carcinogenic potential. Studies to detect mutagenic potential of amoxicillin alone have not been conducted; however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate (AUGMENTIN). Augmentin was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Augmentin was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Augmentin was negative in the mouse micronucleus test and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. In a multi‑generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 2 times the 3 g human dose based on body surface area).